Altered Methylation Patterns of the SRD5A2 Gene in Post-Finasteride Syndrome Patients: A Pilot Study
This pilot study investigates the epigenetic modifications in patients suffering from Post-Finasteride Syndrome (PFS). The researchers focused on the methylation patterns of the SRD5A1 and SRD5A2 gene promoters in cerebrospinal fluid (CSF) and blood samples. The study included 16 PFS patients and 20 age-matched healthy controls.
The results revealed that the SRD5A2 promoter was significantly more methylated in the CSF of PFS patients compared to the controls, while no methylation was detected in blood samples. This methylation may play a crucial role in the altered neuroactive steroid levels observed in PFS patients, potentially leading to the behavioral disturbances associated with the syndrome.
These findings suggest that finasteride treatment may lead to tissue-specific epigenetic changes, which could underlie the persistent symptoms seen in PFS. However, it remains unclear whether these methylation patterns are established prenatally or induced by finasteride treatment itself.
For more detailed information, you can access the original article here.
Learn more about PFS & PSSD
What is Post-Finasteride Syndrome?
PFS (Post-Finasteride Syndrome) is a complex and life-altering condition caused by the drug Finasteride (also marketed as Propecia) and other 5ar inhibitors. It affects physical, mental, and sexual health, leaving patients to suffer without adequate support, recognition or treatment.
What is Post-SSRI Sexual Dysfunction?
PSSD (Post-SSRI Sexual Dysfunction) is a serious and debilitating condition associated with the use of selective serotonin reuptake inhibitors (SSRIs) and similar drugs. It affects mental, physical, and sexual well-being, leaving many patients to suffer without sufficient support, recognition, or effective treatment.
